miniddy5的部落格

為期三天的“競投及管理國際會議工作坊”課程，儲存吸引不同範疇的會展從業員參加。有學員認為，工作坊由國際團隊授課，視野、眼光較國際化，可分享世界不同地方的競投經驗，有助擴闊個人視野，亦能知道自身的不足。學會訂定市場方向澳門威尼斯人會展旅遊市場策劃主任李軍樺是課程學員之一。她認為，本澳定位為世界旅遊休閒中心，會展是重要一環，近年也有不少遊客來澳參加展覽、開會及旅遊，可預見行業的發展空間及存在必要性。是次課程教懂學員以廣闊目光維持業界關係、訂定市場發展方向，有助業界知其不足，加以改善。有六年會展經驗的澳門博覽集團有限公司展覽部經理關桂芬表示，作為一間展覽組織公司，有責任帶領與會者感受澳門，但一直忽略服務與會者的工作，學而知不足，會針對提高服務水平。會展業可接觸不同範疇，如醫學、科技等的專業人士，互相交流意見，十分熱愛目前職業。旅遊塔會展娛樂中心業務發展總監潘雁翎認為，近年政府投放在會展業的資源增加，機會較以新蒲崗迷你倉多，硬件配套充足。如近年各大專院校積極培訓人才，為會展業增添新血。本澳訂下了正確的發展方向，會展業亦開始起步，發展速度的快與慢需取決於各方的配合。抓緊地標宣傳城市潘雁翎及李軍樺稱，身為會展業的場地提供者，希望以本澳作為目的地，投標不同會議，吸引更多人來澳。從課程中學會以國際性管理模式，抓緊本地的標誌去宣傳城市，更要承擔企業的社會責任。學員認為，澳門是一片小福地，居民骨子裡存有熱情，具備地理、好客的優勢。但要成功競投一個國際性會議，必須由整個社會帶動，故要做好公交服務、餐飲、環境等配套，為與會者建立一個健康、可持續發展的城市形象。冀能與不同國際人士、社團合作競投，增加競投力量。鄰近不乏會展業成熟的地方，業界競爭相當激烈。她們認為，相較香港，澳門不一定處於劣勢。本地場館價錢較香港便宜，酒店房量多，加上點到點的距離近，參會觀展非常方便。另外，本地具有世遺特色、穩定的社會及人情味等獨特優勢，也有助會展業發展。mini storage

Source: The Blade, Toledo, OhioAug.存倉 20--Sylvania City Council's zoning and annexation committee has decided to recommend no changes to a city ordinance setting a three-dog limit for residential properties.During an hour-long hearing Monday evening, committee Chairman Doug Haynam told Jean Keating, whose provision of foster homes for dogs prompted a neighborhood complaint in July, that her neighbors believed she had impaired their enjoyment of their properties and thus council had no burden to change the city law.Ms. Keating, who fosters dogs for the Lucas County Pit Crew -- a non-profit organization she founded that provides temporary homes, pending adoption, of "pit bulls" and other rescue animals -- had lobbied council to abolish a portion of the city code pertaining to kennels that places a three-dog limit in residential and non-industrial business zones.Zoning administrator Bob Oberly said he had visited Ms. Keating's home twice in July based on a complaint regarding dogs jumping on the fence, noise, and odor. At that time she had nine dogs at her home, three of which are her licensed pets. He told her she was in violation of the law.However, Ms. Keating said she believes dogs are property and if one can effectively manage to care for them, the government does not have the right to place limits."I think this is cut-and-dried. I don't have a say about how many kids, guns, or cats people can have," she said after the committee's decision to let the law stand.She said she cleans her y自存倉rd of feces daily, and that the constant barking was from a neighbor's dog, since she places the dogs in crates inside her home when she works or is away.Others who were in favor of changing the law, and have been active in dog rescue or fostering activities, sat in the council chambers wearing T-shirts that showed their support for animal care.Ms. Keating questioned how the city could restrict animal ownership, when there is an Animals and Fowls Code that addresses animal nuisances and safety to neighbors."What one person thinks is proper care another person may not agree," Mr. Haynam said.Ms. Keating replied that dogs are property, and "you're limiting what I can own."Mr. Haynam agreed with that statement, saying residents do not have unlimited property rights, especially when the property may infringe on another person's peace and quiet."We have a lot of people living in close proximity to one another, and we have rules and ordinances in place to keep the peace," he said, adding that establishing a dog limit at three per household is an objective way to maintain peace citywide.Afterward Ms. Keating said she would continue to carry out her animal fostering activities, and vowed to challenge the city code in court if cited again for violating the dog-limit ordinance.Contact Natalie Trusso Cafarello at: 419-206-0356 or ntrusso@theblade.com.Copyright: ___ (c)2013 The Blade (Toledo, Ohio) Visit The Blade (Toledo, Ohio) at .toledoblade.com Distributed by MCT Information Services迷你倉新蒲崗

Source: Montgomery Advertiser, Ala.迷你倉新蒲崗Aug. 20--Let's not kid ourselves about what the Camellia Bowl really is.It is another in a long line of meaningless, low-level bowl games that pit two teams from lesser conferences against each other in a contest that will serve as the background noise at your office/family/neighborhood Christmas party.And, oh, yeah, it's also great for this city.That might seem like an odd thing to say after the description of the game, but it can be both. Let me explain.First of all, Montgomery's downtown has undergone a revitalization the last few years. We've spent a boatload of money both building and renovating facilities and making improvements required to attract high-profile businesses, like the Renaissance Montgomery Hotel & Spa at the Convention Center.All of that construction and renovation, which is still ongoing, was done, at least in part, to attract events to the city. Events bring in people. People spend money. Money translates into taxes. Tah-dah, the renovations are starting to pay for themselves.The thing is, though, at some point, you have to stop renovating and start attracting. You have to cash in on the investment.This Camellia Bowl is the first big step toward that end.It is Montgomery's opportunity to prove to the sports world -- through ESPN, the sports world's biggest mouthpiece -- that it has the facilities, the infrastructure, the people and the fans to support mid-level events.And let's be real here, the middle of the ladder is all we're shooting for in this city. Not because of a lack of initiative or an unwillingness to be more, but because this isn't a major city. Montgomery's never going to be in the business of bidding for Super Bowls or NCAA basketball finals.It is what 迷你倉出租t is.But make no mistake about it, terrible game or not, people will be watching. Because it's major college football.Every year, we go through this ordeal of people complaining about the number of bowl games, insisting that the addition of more bowls somehow cheapens the sport and the bowl season. They want to go back to the days of just a handful of bowls played right around and on New Year's Day and that be the end of it.And to support their argument, they insinuate that no one is watching these low-level bowl games.And every year, every TV executive is saying the same thing: Shut up.These little bowl games, like the Camellia Bowl, pull in very decent ratings. Because A. It's football, and B. What else are you going to watch in mid-December? Early season NBA games?That's why this is so important to Montgomery."We have to show ESPN that we can do this," Montgomery Mayor Todd Strange said. "We have a six-year deal in place. We expect to meet their expectations and improve every year. After that, who knows what opportunities might be out there for us?"Some opportunities are already in play.Strange said he and city leaders have discussed with ESPN officials the possibility of other sports events -- both football and other sports -- being located in Montgomery, depending, of course, on how this bowl game contract goes.Should those deals pan out, it would mean more money for city businesses. More tax revenue. More jobs. And better PR for Montgomery.This is our shot. Just don't blow it.Josh Moon is an Advertiser reporter and columnist.Copyright: ___ (c)2013 the Montgomery Advertiser (Montgomery, Ala.) Visit the Montgomery Advertiser (Montgomery, Ala.) at .montgomeryadvertiser.com Distributed by MCT Information Services儲存倉

未能提供文字內容。.自存倉scmp.com/comment/insight-opinion/article/1297832/has-hong-kong-lost-its-mind

LONDON, Aug.迷你倉出租 19, 2013 /PRNewswire/ -- Ogilvy Public Relations (Ogilvy PR), announced today that Marshall Manson has been appointed Managing Director, EAME Social@Ogilvy. Manson brings more than 15 years expertise in building effective and award-winning digital and social campaigns. Manson joins from Edelman where he was Managing Director of Digital for EMEA. He will report to Stuart Smith, CEO of Ogilvy PR EAME.In his new role, Marshall will provide leadership on social for all disciplines across EAME, with a strong emphasis on earned media and content.Stuart Smith, CEO of the EAME region for Ogilvy PR said:"Marshall's hire signals our continued commitment to help clients take advantage of the disruptions to traditional communications models across the marketing mix. We are growing strongly in EAME by demonstrating leadership in integration, social and content. We have made several key social leadership hires in markets such as UK, South Africa, Spain and France in recent months. Marshall is a formidable digital and social strategist with a reputation for generating creative campaign solutions for brands. He is a seasoned leader with truly international experience and a deep thinker. I am delighted he's joining us. He's a great fit for Ogilvy."John Bell, Global Managing Director of Social@Ogilvy said:"We are past the pioneering stage. Now we must scale and innovate in social at the same time. No simple feat and Marshall brings great skills doing just that. He joins a truly global network of digital experts at Ogilvy & Mather and will be a key part of our worldwide leadership in Social@Ogilvy."During his time at Edelman, Manson created and executed successful digital and social media marketing strategies for global consumer brands including, Diageo's Johnnie Walker. He has also developed and implemented online reputation management strategies for a wide range of corporate clients, such as HP and AstraZeneca and helped clients manage complex issues and crises breaking in social media.About his appointment, Manson said:"This role was irresistible to anyone who understands that an integrated approach to paid, owned and earned media is the future for marketing and communications. Given all the changes that social media is driving in our industry, there is nowhere I'd rather practice creative, edgy and effective campaigns for brands than an integrated communications firm full of smart people which is enjoying great growth and winning awards. I am excited by the new role and looking forward to working with colleagues across all disciplines and strengthening Ogilvy's leadership, which is delivering real value to our clients' brands and bottom line."Manson will join in October 2013. He started life as a political campaigner, creating TV and radio ads along with direct mail for candidates in the U.S. He has lived in London since 2008. He graduated from Hampden-Sydney College with a degree in political science in 1996, and now lives in London with his wife, Stephanie儲存倉 and their beagle, Cody.Notes to Editors:Ogilvy PR's EAME network is growing rapidly and now includes 45 offices and affiliates. In 2012, Ogilvy PR's EAME region took home two gold European SABRE Awards and was highly commended in the Best Pan-European Consultancy to Work For category in the Holmes Report Best Consultancies survey. Recent client roster additions include Confused.com, Google, European Parliament, Reed Smith, Trollbeads and KFC.About Social@Ogilvy:Social@Ogilvy is the world's largest network of social media strategists. Named 2011 Global Digital/Social Consultancy of the Year by The Holmes Report, the practice leverages social media expertise across all Ogilvy & Mather disciplines, offering an extensive list of services within the foundational business solutions -- Listening and Analytics; Social Business Solutions; Social Media Marketing and Communications; Social Shopping; Social CRM; Social Care; and Conversation Impact(TM).About Ogilvy Group:Ogilvy & Mather is one of the largest marketing communications companies in the world. In 2012, O&M was named Cannes Lions Network of the Year and Most Effective Agency Network by the Effies Global Effectiveness Index. The company is comprised of industry leading units in all of the following disciplines: advertising; public relations and public affairs; branding and identity; shopper and retail marketing; healthcare communications; direct, digital, promotion and relationship marketing; consulting, research and analytics capabilities; branded content and entertainment; and specialist communications. O&M services Fortune Global 500 companies as well as local businesses through its network of more than 450 offices in 120 countries. It is a WPP company . For more information, visit .ogilvy.com, or follow us on Twitter at @OgilvyWW and on Facebook.com/Ogilvy.About Ogilvy Public Relations:Ogilvy Public Relations (Ogilvy PR) is a global, multi-disciplinary communications leader operating in more than 85 offices across six continents. In 2012, Ogilvy was named Cannes Lions Network of the Year and Most Effective Agency Network by the Effie Global Effectiveness Index, named Public Affairs Consultancy of the Year by the Holmes Report, won Consumer Consultancy of the Year in Asia Pacific (Holmes Report), and won the WPP global, top award (WPPed Cream, Creme de la Creme) for the fifth time in six years. Ogilvy PR integrates deeply with all Ogilvy & Mather disciplines (advertising, direct marketing, activation, promotional, digital and entertainment) through the proprietary Ogilvy Fusion(TM) approach to delivering comprehensive, business solutions through content creation, community building, and communications with measurable results. Ogilvy PR is a unit of Ogilvy & Mather, a WPP company , and one of the largest marketing communications companies in the world. For more information, visit our website at .ogilvypr.com or follow us on Twitter at @ogilvypr.Ogilvy Public RelationsWeb site: .ogilvy.com/.ogilvypr.com/迷你倉沙田

本報訊（首席記者梁峽林 實習生趙陽）18日，存倉2013青城古鎮文化旅遊節開幕。“青城古鎮文化旅遊節”自2007年開辦以來，至今已是第5次舉辦。本次節會主要由文化藝術作品展、非物質文化展演、國學經典朗誦活動、農民文藝節目演出、攝影比賽、遊客互動活動、青城古鎮文化旅遊節推介活動等七部分組成。有剪紙刺繡、書畫等文藝作品展出，有國學講座和國學經典朗讀，有秧歌、秦腔等農民文藝表演，有遊客互動劃船比賽、垂釣比賽和賞花等活動。參加本次節會的人數比往年要多，來自10個村的300余群�參加扭秧歌表演，有200余人參加國學經典誦讀比賽。

　　【中新社北京8月19日電】中國國家主席習近平19日下午在人民大會堂同肯亞總統肯雅塔舉行會談。兩國元首就發展雙邊關係深入交換意見，self storage對中肯關係的發展表示滿意，著眼未來，決定建立平等互信、互利共贏的中肯全面合作夥伴關係。　　習近平表示，中肯友好交往源遠流長。中國明代著名航海家鄭和曾率遠洋船隊多次訪問肯亞。兩國建交50年來，雙邊關係保持全面快速發展。你的這次訪問是兩國新一屆領導人首次會面，對開創中肯友好合作關係新局面具有重要意義。中方願同肯方共同努力，發展平等互信、互利共贏的全面合作夥伴關係。　　習近平強調，中肯雙方要在涉及彼此核心利益和重大關切的問題上繼續相互支持，深化政黨、立法機構、地方政府間交往，開展治國理政經驗交流。中方願繼續採取積極措施從肯方增加進口，促進雙邊貿易平衡增長。雙方要加強基礎設施、經濟特區建設、投融資等領域合作，在新能源、農業、環境和野生動物保護等領域培育新的合作。希望兩國執法部門加強合作，共同打擊跨國犯罪。雙方要共同採取措施，便利人員往來，鼓勵文化、旅遊、青年、人力資源培訓等領域交流合作，共同辦好在肯亞舉行的「感知中國」等兩國建交50周年慶祝活動。中肯在重大國際和地區問題上看法相同或相近，雙方要繼續保持協調和配合，共同維護發展中國家正當權益。　　肯雅塔表示，肯中傳統友誼深厚，鄭和下西洋在肯亞播撒了友誼。此後，肯亞一直是連接非洲和中國的重要紐帶。肯亞人民感謝中國長期以來支持肯亞國家迷你倉立和民族解放事業，欽佩中國悠久的歷史文明和巨大的改革開放成就，相信中華民族的偉大復興正在呈現光明的前景，中國將為促進世界和平、穩定和繁榮發揮更大作用。肯亞正在致力於實現工業化，提高人民生活水準。相同的歷史命運和共同的未來願景把肯中兩國緊密連在一起。肯亞將中國視為真誠的朋友和重要的夥伴，希望借鑒中國的成功經驗，以兩國建立全面合作夥伴關係為契機，加強在政治、經濟、人文等領域和國際事務中的合作，開啟兩國關係更加美好的新時代。　　習近平指出，當前，和平、發展、合作、共贏的時代潮流更加強勁，新興市場國家和發展中國家整體實力增強，國際力量對比朝著有利於維護世界和平方向發展。非洲人民求和平、思穩定、謀發展意願空前強烈。中非從來都是命運共同體。中方堅定支持非洲國家自主發展和聯合自強，願為促進非洲和平穩定和發展振興繼續發揮建設性作用。　　肯雅塔表示，肯方高度讚賞中國幫助非洲、支援和平解決非洲地區熱點問題，希望中方為促進非洲和平穩定和發展繁榮發揮更大作用。肯方願同中方一道，加強中非合作論壇建設，推動非中友好合作關係不斷發展。　　會談後，兩國元首共同出席了兩國政府經濟技術合作協定以及便利人員往來、融資、環保、新能源等領域雙邊合作檔簽字儀式。　　會談前，習近平在人民大會堂東門外廣場為肯雅塔舉行歡迎儀式。習近平主席夫人彭麗媛、全國人大常委會副委員長張寶文、國務委員楊潔篪、全國政協副主席羅富和、九三學社中央常務副主席邵鴻等出席。文件倉

50歲食道癌患者陳克仰2年前因吞嚥困難、胃食道逆流，儲存以為是長期日夜顛倒所致，他直到昏倒送醫才發現是食道癌末期，如今他抗癌成功，可以開心進食，昨天他在台中榮總「好呷俱樂部」食道癌病友會分享抗癌經驗。台中榮總外科部主任徐中平說，食道癌初期無明顯症狀，約有8成患者發現時已經是第3期，合併口腔癌約2到3成，避免食道癌上身方法，除少碰菸酒、檳榔等高危險因子外，高危險群包括抽菸、喝酒、嚼檳榔族群，以及頭頸癌患者等，從45歲開始，每年應接受胃鏡篩檢。陳克仰年輕時曾長期擔任大夜班保全工作，40歲時身體出狀況，易疲累，因此辭掉工作並戒菸，2年前，陸續出現吞嚥困難、體力變差、解黑便、胃食道逆流，他以為是以前日夜顛倒所致，直到昏倒送醫，確診為食道癌4期，他才明白身體出狀況的原因。陳克仰說，他選擇面對，切除腫瘤後，因食道狹窄，適新蒲崗迷你倉期長達9個月，除家人支持，他也看美食節目「解饞」，好不容易熬過去，他第一口嚐到美食是廣東粥，覺得能大口享受食物是件幸福的事。另名55歲病友胡興安是家庭代工老闆，為人熱情的他喜歡與朋友喝二杯，一天抽1、2包菸，3年前因吃東西覺得卡卡的，確診為食道癌3期，他接受放療、化療後，原本要接受手術，但因手術前，他為好友拈香，沒想到高燒不退、肺衰竭，在加護病房住了22天，無法再接受手術，他在接受醫師安排的放療、化療後，癌症降為零期，每3個月回診追蹤。胡興安形容自己是「鬼門關前走一遭」，讓他更珍惜生命，他以前是綽號「大砲」，脾氣很大，因這次生病改很多，除戒菸、戒酒、遵從醫囑，也培養唱歌、種花和每天走路4000公尺紓壓，更重要是學會放下、感謝，現在體力、胃口都比以前好，他感謝家人支持、陪伴與醫護人員醫治，讓他能迎接新的人生。mini storage

bjrb.bjd.com.cn/html/2013-08/20/content_101022.htm...正規旅行社黯然退出“一日游”市場 本報記者 楊汛 實習生 徐盼 “劣幣驅逐良幣”的現象，自存倉正在“北京一日游”市場中悄然蔓延。昨日，...

新華社北京8月19日電 國家主席習近平19日在人民大會堂同肯尼亞總統肯雅塔舉行會談。兩國元首就發展雙邊關係深入交換意見，儲存倉對中肯關係的發展表示滿意，著眼未來，決定建立平等互信、互利共贏的中肯全面合作伙伴關係。習近平表示，中肯友好交往源遠流長。中國明代著名航海家鄭和曾率遠洋船隊多次訪問肯尼亞。兩國建交50年來，雙邊關係保持全面快速發展。你的這次訪問是兩國新一屆領導人首次會面，對開創中肯友好合作關係新局面具有重要意義。中方願同肯方共同努力，發展平等互信、互利共贏的全面合作伙伴關係。習近平強調，中肯雙方要在涉及彼此核心利益和重大關切的問題上繼續相互支持，深化政黨、立法機構、地方政府間交往，開展治國理政經驗交流。中方願繼續採取積極措施從肯方增加進口，促進雙邊貿易平衡增長。雙方要加強基礎設施、經濟特區建設、投融資等領域合作，在新能源、農業、環境和野生動物保護等領域培育新的合作。希望兩國執法部門加強合作，共同打擊跨國犯罪。雙方要共同採取措施，便利人員往來，鼓勵文化、旅遊、青年、人力資源培訓等領域交流合作，共同辦好在肯尼亞舉行的“感知中國”等兩國建交50周年慶祝活動。中肯在重大國際和地區問題上看法相同或相近，雙方要繼續保持協調和配合，共同維護發展中國家正當權益。肯雅塔表示，肯中傳統友誼深厚，鄭和下西洋在肯尼亞播撒了友誼。此後，肯尼亞一直是連接非洲和中國的重要紐帶。肯尼亞人民感謝中國長期以來迷你倉沙田持肯尼亞國家獨立和民族解放事業，欽佩中國悠久的歷史文明和巨大的改革開放成就，相信中華民族的偉大復興正在呈現光明的前景，中國將為促進世界和平、穩定和繁榮發揮更大作用。肯尼亞正在致力于實現工業化，提高人民生活水平。相同的歷史命運和共同的未來願景把肯中兩國緊密連在一起。肯尼亞將中國視為真誠的朋友和重要的伙伴，希望借鑒中國的成功經驗，以兩國建立全面合作伙伴關係為契機，加強在政治、經濟、人文等領域和國際事務中的合作，開�兩國關係更加美好的新時代。習近平指出，當前，和平、發展、合作、共贏的時代潮流更加強勁，新興市場國家和發展中國家整體實力增強，國際力量對比朝著有利於維護世界和平方向發展。非洲人民求和平、思穩定、謀發展意願空前強烈。中非從來都是命運共同體。中方堅定支持非洲國家自主發展和聯合自強，願為促進非洲和平穩定和發展振興繼續發揮建設性作用。肯雅塔表示，肯方高度讚賞中國幫助非洲、支持和平解決非洲地區熱點問題，希望中方為促進非洲和平穩定和發展繁榮發揮更大作用。肯方願同中方一道，加強中非合作論壇建設，推動非中友好合作關係不斷發展。會談後，兩國元首共同出席了兩國政府經濟技術合作協定以及便利人員往來、融資、環保、新能源等領域雙邊合作文件簽字儀式。會談前，習近平在人民大會堂東門外廣場為肯雅塔舉行歡迎儀式。習近平主席夫人彭麗媛、全國人大常委會副委員長張寶文、國務委員楊潔篪、全國政協副主席羅富和等出席。迷你倉價錢

　　西班牙一間建築公司，迷你倉價錢計劃在南美洲國家秘魯首都利馬市外圍臨海懸崖邊上，興建一座傾斜酒店。該間可遙望太平洋的酒店，設計有如傾斜的方形相架，予人搖搖欲墜的感覺；而酒店中間更有一個方形空洞，避免阻擋太平洋景觀。但建築方案仍有待利馬城市規劃官員審批，一旦落實有望成為利馬地標。

沒有內文

隱形眼鏡龍頭公司F-金可（8406）於上周五（16日）舉辦法說會。法人推估F-金可在第3季營收挑戰13.8億，文件倉季增約10％，預期將會是全年最旺一季，其熱門認購權證可留意。F-金可表示，今年底中國大陸、台灣各有3條、1條產線建置完成，預估明年首季初投產，總產能將提高到15條。而第4季海儷恩、海昌都將推出新系列產品，營收有機會維持高檔。在台灣新產能利用率拉高下，預估毛利率逐季攀升，法人預估，下半年每股盈餘挑戰9元，較上半年成長3成，全年每股盈餘逾16元。過去中國大陸市場以長拋為主，近2年轉短拋趨勢顯著，上半存倉短拋占比已達3成，下半年預估將達35％，因應短拋市場的成長，已透過自動化改善製程，台灣5條產線中，已完成1條產線轉換，出貨量提高3成，明年初投產4條產線產能也全數提高3成，成為未來支撐業績重要推手，長期目標希望能與國際品牌的年產能2800萬片接近。元富新金部建議，看好F-金可的投資人可以選擇元富X6（709018），價外9.21％，剩餘天期155日及凱基PC（708410），價外3.84％，剩餘天期123天。＊【權證投資必有風險，本專區資訊僅供參考，並不構成邀約、招攬或其他任何建議與推薦，請讀者審慎為之】自存倉

大陸最大商業地產企業─大連萬達集團董事長王健林，mini storage昨在彭博全球億萬富豪排行榜（BLOOMBERG BILLIONAIRES INDEX），以142億美元身價，坐上大陸首富的寶座。王健林不僅超越身價110億美元的娃哈哈集團總裁宗慶后，成為大陸新首富，同時還是彭博排行榜亞太區第六（第一是李嘉誠）、全球排名66的世界級富豪。據公開資訊顯示，萬達集團擁有商業地產、高級酒店、旅遊、文化產業與連鎖百貨等5大產業；企業資產2200億元人民幣（下同）、年營收1051億元。目前大陸各地已開業的萬達廣場有72座、五星酒店28家、40家百貨公司、45家量販KTV；萬達集團預估到2015年，營收將成長到2000億元。根據彭博資料指出，王健林旗下房產公司，管理了416self storage坪房產，其中多數屬商業地產。一位在大連從事地產業台商透露，萬達集團土地多數低價取得，在大陸各城市店面租金飛漲下，王健林成為首富，一點不意外。雖然萬達集團旗下企業都沒有股票上市，但彭博透過同業推估，這位大陸新首富在萬達商業地產公司的持股，應有74億美元價值，萬達百貨持股則約56億美元；僅以這兩大資產計算，就足以讓王健林成為大陸首富。如同許多大陸富豪，在依靠大陸市場賺大錢後，往往會把投資目標朝向海外，王健林不例外；他分別在2012年以26億美元收購了AMC，讓萬達集團成為全球最大電影院連鎖集團。今年6月還斥資16億美元，收購英國SUNSEEKER INTERNAITONAL LTD.遊艇公司；並規畫未來將投資10億美元，在倫敦泰晤士河沿岸興建豪宅。迷你倉

Source: Erie Times-News, Pa.mini storageAug. 19--If things had worked out the way he planned in high school, Mike Ruzzi might have been writing this column about someone else.Ruzzi wanted to be a sportswriter growing up in South Park Township, the Pittsburgh suburb where he played football and wrestled and spent one year on the tennis team and dreamed of turning his love of sports into a profession.He did, but not by putting words on a page. Instead, Ruzzi entered an essay contest through a Pittsburgh television station. He won a scholarship and a six-week internship at the station, WIIC, sending him head-first into broadcasting.After graduating from Edinboro University in 1982, he spent 21/2 years working part time at WSEE and WICU before replacing Phil Fatica as WICU's sports anchor, a position a held until Sunday."It was never my intention to get into TV, but it worked out that way," said Ruzzi, 51, who ends a nearly 30-year career on Erie's sports scene today when he officially becomes co-anchor for four daily newscasts on WICU.Three decades is no short run, and during that time Ruzzi has covered six Super Bowls, a Daytona 500, an Indianapolis 500, numerous high school state championships and countless features.The first one was a package Ruzzi created on Buffalo Bills special teams maven Lou Piccone while still an intern with WJET in 1982.He lists among his favorite moments broadcasts of Strong Vincent's 1991 PIAA football championship, two Girard boys state basketball championships and the unforgettable 1987 PIAA basketball meeting between Carlisle, led by future NBA player Billy Owens, and a Meadville powerhouse led by the Burnett brothers, Paul and Michael.Ruzzi also has worked closely with Erie City Special Olympics since he was encouraged in the early 1990s to become involved as its banquet emcee by former Strong Vincent assistant basketball coach Jim Delsandro.That work, as much as anything he's covered in sports, has left lasting memories.At an event at Penn State Behrend in April, Ruzzi raced a Special Olympian named Willie. In a wheelchair decked out in Steelers logos, Willie pulled away for an easy win, then dazzled Ruzzi with a detailed forecast of the Steelers' draft prospects."I'll never forget the smileself storageon his face when he got to the finish line," Ruzzi said.As with most professions, technology has taken quantum leaps since Ruzzi broke in. In the early years he would rush back to the station after an NFL game and spend hours editing packages against deadline for the 11 p.m. newscast. Now he does the same work on-site in an hour or less and zaps it back to Erie.What hasn't changed is Ruzzi's calling card, an upbeat approach to stories and sources he says comes from five years working alongside former WICU sportscaster Craig Woodard.When Ruzzi took time off in 2001 to be with his father, who was battling cancer, Woodard picked up the extra shifts. After Ruzzi's father died, Woodard worked a Friday night, left early the next morning with a few colleagues to drive to Pittsburgh for the funeral, then returned to Erie to work that night, making it clear he had Ruzzi's back for as long as he needed him."He taught me to look at things with a glass-half-full attitude," Ruzzi said of Woodard, who now works in the financial services industry in Florida. "He had so much positive energy, and that made a real impression on me."Ruzzi has the same sort of close relationship with longtime sidekick Jay Puskar, who will replace him in sports beginning today. Tim Melo, a versatile cameraman/reporter for the station for the past several years, will slide into Puskar's role.Sunday, Ruzzi was back at his parents' home in South Park Township for a helping of his mother's "good luck lasagna" on the eve of today's news desk debut. He admits to having heard from a few skeptics wondering how a sports guy will fare in the news world.But he's not worried about the switch, pointing out that WICU's previous two sports anchors -- Fatica and the late Bill Knupp -- made successful moves to news."Reporting is reporting, whether it's news or sports," Ruzzi said.And, as he learned a long time ago, landing in front of the camera can be a nice fallback plan for an aspiring writer.JOHN DUDLEY can be reached at 870-1677 or john.dudley@timesnews.com. Follow him on Twitter at twitter.com/ETNdudley.Copyright: ___ (c)2013 the Erie Times-News (Erie, Pa.) Visit the Erie Times-News (Erie, Pa.) at .GoErie.com Distributed by MCT Information Services迷你倉

Triathlon clubs offer a chance for amateur athletes and children to train with champions, writes Rachel JacquelineTo the casual observer, a triathlon seems like a torture fest.文件倉 It’s an exhausting combination of swimming, cycling and running, interrupted by a flurry of transitions.But that hasn’t fazed the thousands of Hongkongers who take part in triathlons each year. Hong Kong’s triathlon association has 2,500 members and is growing, says Fenella Ng, executive committee member of the Hong Kong Triathlon Association.“Membership has increased by around 10 per cent every year since 2008. We now have 31 affiliated clubs and the HK ITU and Age-Group race held annually at Disneyland has a sell-out capacity of 2,000 entries,” she says.“There is a growing participation across the board: children, adults, corporate relay and, more recently, the introduction of the para-triathlon.”Joining a triathlon club is a great way to become acquainted with the local fraternity, get coaching and find training buddies. Here are a few that are making waves in Hong Kong’s triathlon scene – and details on how you can become part of it.TRITONS TRIATHLON CLUBtritonstriathlon.com and hku.hk/ihp/triathlonStriking a balance between scientific training and having fun is the philosophy of the Tritons Triathlon Club. Founded in 2008 by former Olympians Annemarie Munk, Fenella Ng and Michael Tse, the club is firmly rooted in performance.“We pride ourselves on top quality coaching and education, as well as providing a balanced approach to suit athletes of all calibres,” says Tse, a performance coach. “We provide an environment where we really want our members to learn to improve to reach their goals.”Most of the Tritons train together through the club’s affiliated triathlon training programme based at the Institute of Human Performance at University of Hong Kong’s Pok Fu Lam campus. The partnership provides members with access to coaching, scientific testing, seminars and performance clinics.But there’s also a seriously social side to the group, with many get-togethers held throughout the year. Training, socialising, and travelling to training camps and races add to the camaraderie, says Ng, the swimming coach and club president.“The Tritons really train and compete hard, but having fun is also a big part of it,” she says.“Being part of a triathlon team is very rewarding in terms of support from teammates, and it’s a great way to meet like-minded people,” adds Tse, who believes it’s the club atmosphere that drives the Tritons’ success.“Our club consistently ranks among the top few age-group teams in Hong Kong and many of our members succeed at international age-group triathlons of all distances from the Olympics to Ironman.”Most of the Tritons’ 200 members are professionals in their 30s and 40s; they are a driven lot who all have one thing in common: a hunger for improvement. “Most of our members are extremely motivated and want to achieve something,” says Tse. “But ultimately, it’s not only about the podium; it’s about individuals challenging themselves to be the best they can be.”HOPE SPORT ASSOCIATIONhopesport.comInspired by the 2008 Beijing Olympics, lifelong friends Marie-Christine Lee and Linda Cheng established the Sports For Hope Foundation to support the next generation of young athletes. Funded by the foundation, the Hope Sport Association offers a quality triathlon training schedule for underprivileged children.“We believe in giving everyone the equal opportunity to explore their potential despite their financial situation,” says head coach Lewis Lam.Open to any child aged between eight and 16, the initiative includes a subsidised training programme, with access to equipment and gear.Technical ability is not a prerequisite to join. “We can train them to be able to take part in triathlons,” Lam says. “The most important thing is that they are interested in sport and, in particular, triathlons.”Hope Sport triathletes can train up to six days a week at venues in Kowloon Tong and Sha Tin and regularly take part in local competitions. Thirty children they traine存倉 took part in the Standard Chartered Hong Kong Marathon 10-kilometre race this year.“Youngsters have so much potential in sport,” says Lam. “They have the time and energy to be developed, both physically and mentally.“The most significant improvement I see in the children is in their mental strength, followed by physical strength. They’re more positive after training and feel more confident.” (Membership subject to interview.)SONIC TRIATHLON GROUPsonicsports.org.hkThe Sonic Sports Association is more like a family than a triathlon group, says club secretary Charles Hui.“We train together, race together, travel overseas together and even eat together – you often see each other more than your family members,” adds fellow club secretary Gigi Leung.Co-founded 10 years ago by ex-national triathlete Kenneth Yip and distance runner Kent Wong, Sonic began as a way to offer high-performance training in the heart of the city.“I wanted to share triathlon with the office guys,” says Yip. “They work long hours, so I wanted them to be able to practise and benefit from my experience training as an elite triathlete in a convenient location.”Back then, Sonic comprised only 10 beginners. Today, the club boasts 150 registered members, 50 of which train actively, and 10 junior athletes from the National B Squad trained by Yip.Two times a week, they train at the Wan Chai sports complex in both running and swimming. The weekends are dedicated to cycling and brick training (combining the different sports together in one intense workout) in Shek O.“It’s a combination of beginners, those looking for fitness and those looking to train up for races,” says Hui. “We are a very friendly club, very easy-going,” he adds. “It’s about self-improvement and having fun – performance comes second. However, when we do well, we celebrate.”It’s a modest approach for a club which ranked seventh in performance among Hong Kong’s 30 triathlon clubs last year. Almost all members found out about the club through word of mouth. “My old coach and a friend who was a member recommended it to me,” says new member Jonathan Zamora. “I work near Wan Chai and the cost was reasonable, so I thought it all made sense. I’m really enjoying it.”26 COACHING – YOUTH DEVELOPMENT PROGRAMME26coaching.comLeading the way in elite triathlon training and youth development is 26 Coaching. The brainchild of national triathlete and former U23 Asian champion Andrew Wright, the organisation has really made a mark on the triathlon scene in Hong Kong since it was established a year ago.Wright offers elite training to a handful of clients, including Kate Rutherford and Olaf Kasten, the best non-professional “age-groupers” in Asia, as well as youth training for 100 children, up to seven days a week.“The community aspect is a huge thing. It’s a great atmosphere and everyone’s pushing for great results,” he says. Wright is joined on his coaching team by Rutherford and Zeco Wan.Plugging what Wright considers a huge gap in youth triathlon training on Hong Kong Island, he recently established a fully supported Youth Development Squad. His intention is to turn his hand-picked athletes into future Olympians. They train with Wright up to seven days a week, free of charge, and are also offered kits and nutrition sponsors.“There’s some unbelievable talent here in Hong Kong,” says Wright. “I think people here push very hard from a young age. There’s that kind of mentality – when they do something, they really apply themselves.”Wright’s selection represents not just the best, but the most committed young triathletes in the city. “Some people are naturally talented, but that will only take you to a certain level. If you look at any triathlete who is any good, they will be training a lot.”At present, there are seven athletes on the programme, and Wright would like to see the number grow.“We’d like to grow the programme to as big as we can. We wanted to cap it at 10, but our main goal is to build young local athletes who can compete at an international level. The more the better, as long as the commitment is there.”life@scmp.com自存倉

NEW YORK, Aug.儲存 19, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:Molecular Diagnostics in Infectious Disease Testing.reportlinker.com/p0368860/Molecular-Diagnostics-in-Infectious-Disease-Testing.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_DiagnosticThis TriMark Publications report describes the specific segment of the in vitro diagnostics market known as molecular diagnostics testing for infectious disease. In the current medical diagnostics market, molecular diagnostics in infectious disease testing offers one of the most promising areas for growth and innovation. The confluence of breakthroughs in genomics and proteomics--along with the development of microarray devices to measure analytes in the blood--has led to this revolutionary market development. Specifically, molecular diagnostics offers the power of advanced analytical techniques to diagnose infectious diseases. Whereas before, the detection of many infectious agents was slow and expensive due to reliance upon culturing methods, researchers are now at the cusp of overcoming such limitations via the use of nucleic acid-mediated molecular diagnostics testing. The purpose of this report is to describe the emerging field of molecular diagnostics in infectious disease testing. The infectious disease space is the most dominant and profitable sector of molecular diagnostics. Topics covered in this study include: 1) the existing and emerging technologies in the field, 2) the U.S. and global market size for molecular diagnostic products and 3) the profiles of companies that are focusing on the molecular diagnostic sector. The research examines drivers and restraints for sales growth, market share and technical trends. In addition, an in-depth analysis of the competitive situation of prominent market venders is provided with five-year sales forecasts.1. Overview 161.1 Statement of Report 161.2 About This Report 171.3 Scope of the Report 171.4 Objectives 191.5 Methodology 191.6 Executive Summary 212. Introduction to Molecular Diagnostics for Infectious Disease Testing 292.1 Molecular Diagnostics Testing and Opportunities in the Infectious Disease Sector 292.2 The Infectious Disease Problem 332.3 Impact of the Human Genome Project on Molecular Diagnostics 372.4 Opportunities for Molecular and Clinical Diagnostics 382.4.1 Companion Diagnostics 392.5 Development of Molecular Diagnostics Testing Markets 392.6 Target-Based Gene Amplification 412.6.1 Polymerase Chain Reaction 412.6.2 Real-Time PCR 412.6.3 Nucleic Acid Sequence-Based Amplification 422.6.4 Market Drivers and Restraints 462.6.4.1 Market Drivers 462.6.4.2 Market Restraints 462.6.5 Market and Technology Trends 462.6.5.1 Market Trends 462.6.5 2 Technology Trends 472.6.6 Strategic Recommendations 482.7 PCR Reagents for Clinical Diagnostics 483. Infectious Disease Diagnostics Molecular Testing Market 503.1 Market Overview 503.1.1 Overall Infectious Disease Market Analysis 553.2 NAT Molecular Diagnostics Market 673.3 Infectious Disease Molecular Diagnostic Testing Markets 693.3.1 HIV 693.3.1.1 Disease Background and Statistics 693.3.1.2 Measuring Viral Loads 763.3.1.3 Instruments and MD Reagents 773.3.1.4 Method Comparisons 833.3.1.5 Market Size 853.3.1.5.1 HIV Diagnostic Testing 863.3.1.6 HIV Market Challenges and Strategic Recommendations 903.3.1.6.1 HIV Molecular Diagnostic Market History 903.3.1.7 Market Drivers and Restraints 913.3.1.7.1 Market Drivers 913.3.1.7.2 Market Restraints 923.3.1.8 Market and Technology Trends 923.3.1.8.1 Market Trends 923.3.1.8.2 Technology Trends 933.3.1.9 Strategic Recommendations 943.3.2 Hepatitis 943.3.2.1 Hepatitis B Virus 953.3.2.1.1 Hepatitis B Disease Background and Statistics 953.3.2.1.2 Instruments and Reagents for Hepatitis B Detection 973.3.2.1.3 Method Comparisons 993.3.2.1.4 Hepatitis B Market Size 1013.3.2.1.5 HBV Market Challenges and Strategic Recommendations 1033.3.2.1.5.1 Market Drivers and Restraints 1033.3.2.1.5.1.1 Market Drivers 1033.3.2.1.5.1.2 Market Restraints 1033.3.2.1.6 Market and Technology Trends 1043.3.2.1.6.1 Market Trends 1043.3.2.1.6.2 Technology Trends 1043.3.2.1.7 Strategic Recommendations 1053.3.2.2 Hepatitis C Virus Testing 1063.3.2.2.1 Disease Background and Statistics 1063.3.2.2.2 Instruments and Reagents for Hepatitis C Detection 1123.3.2.2.3 Method Comparisons for HCV Tests 1183.3.2.2.4 Hepatitis C Market Size 1203.3.2.2.4.1 HCV Market Share 1223.3.2.2.5 HCV Market Challenges and Strategic Recommendations 1233.3.2.2.5.1 Market Drivers and Restraints 1233.3.2.2.5.1.1 Market Drivers 1233.3.2.2.5.1.2 Market Restraints 1243.3.2.2.5.2 Market and Technology Trends 1243.3.2.2.5.2.1 Market Trends 1243.3.2.2.5.2.2 Technology Trends 1253.3.2.2.6 Strategic Recommendations 1263.3.3 Human Papillomavirus 1273.3.3.1 Disease Background and Statistics 1273.3.3.2 Instruments and Reagents for HPV Detection 1323.3.3.3 Method Comparison 1393.3.3.4 HPV Market Size 1393.3.3.4.1 North American Market 1413.3.3.4.2 European Market 1433.3.3.5 Market Challenges and Strategic Recommendations 1453.3.3.5.1 Market Drivers and Restraints 1453.3.3.5.1.1 Market Drivers 1453.3.3.5.1.2 Market Restraints 1453.3.3.5.2 Market and Technology Trends 1453.3.3.5.2.1 Market Trends 1453.3.3.5.2.2 Technology Trends 1473.3.3.5.3 Strategic Recommendations 1493.3.4 Influenza Viruses 1493.3.4.1 Disease Background and Statistics 1493.3.4.2 Instruments and Reagents for Influenza Detection 1553.3.4.3 Method Comparisons 1583.3.4.4 Influenza Market Size 1583.3.4.5 Influenza Market Challenges and Strategic Recommendations 1593.3.4.5.1 Market Drivers and Restraints 1593.3.4.5.1.1 Market Drivers 1593.3.4.5.1.2 Market Restraints 1593.3.4.5.2 Market and Technology Trends 1603.3.4.5.2.1 Market Trends 1603.3.4.5.2.2 Technology Trends 1603.3.4.5.3 Strategic Recommendations 1613.3.5 STD Testing (Chlamydia/Gonorrhea Molecular Diagnostic Testing) 1613.3.5.1 Chlamydia/Gonorrhea Molecular Diagnostic Testing Market Size 1633.3.5.2 Competitive Structure and Market Share Analysis 1633.3.5.2.1 Market Forecasts 1653.3.5.2.1.1 Revenue Forecasts 1653.3.5.3 Chlamydia Molecular Diagnostic Testing 1653.3.5.3.1 Disease Background and Description 1653.3.5.3.2 Product Analysis: Instruments and Reagents for Testing Chlamydia 1693.3.5.3.3 Method Comparison 1713.3.5.3.4 Chlamydia Molecular Diagnostic Testing 1723.3.5.3.4.1 Revenue Forecasts 1723.3.5.3.4.2 Market Challenges 1733.3.5.3.4.2.1 Market Drivers 1733.3.5.3.4.2.2 Market Restraints 1733.3.5.3.5 Market and Technology Trends 1743.3.5.3.5.1 Market Trends 1743.3.5.3.5.2 Technology Trends 1743.3.5.3.5.3 Strategic Recommendations 1753.3.5.4 Gonorrhea Molecular Diagnostic Testing 1753.3.5.4.1 Disease Background and Description 1753.3.5.4.2 Product Analysis: Instruments and Reagents 1783.3.5.4.3 Method Comparison 1803.3.5.4.4 Competitive Structure and Market Share Analysis 1813.3.5.4.5 Market Forecasts 1823.3.5.4.5.1 Revenue Forecasts 1823.3.5.4.6 Market Challenges 1823.3.5.4.6.1 Market Drivers 1823.3.5.4.6.2 Market Restraints 1823.3.5.4.7 Market and Technology Trends 1823.3.5.4.7.1 Market Trends 1823.3.5.4.7.2 Technology Trends 1833.3.5.4.8 Strategic Recommendations 1833.3.6 Tuberculosis 1833.3.6.1 Disease Background and Description 1833.3.6.2 Product Analysis: Instruments and Reagents 1923.3.6.3 Method Comparison 1933.3.6.4 Tuberculosis Market Size 1943.3.6.5 Competitive Structure and Market Share Analysis 1953.3.6.6 Market Forecasts 1973.3.6.6.1 Revenue Forecasts 1973.3.6.7 Market Challenges 1983.3.6.7.1 Market Drivers 1983.3.6.7.2 Market Restraints 1983.3.6.8 Market and Technology Trends 1993.3.6.8.1 Market Trends 1993.3.6.8.2 Technology Trends 2003.3.6.9 Strategic Recommendations 2003.3.7 Methicillin-Resistant Staphylococcus aureus (MRSA) 2013.3.7.1 Disease Background and Description 2013.3.7.2 Product Analysis: Instruments and Reagents 2043.3.7.3 Method Comparison 2053.3.7.4 MRSA Market Size 2063.3.7.5 Competitive Structure and Market Share Analysis 2073.3.7.6 Market Forecasts 2093.3.7.6.1 Revenue Forecasts 2093.3.7.7 Market Challenges 2103.3.7.7.1 Market Drivers 2103.3.7.7.2 Market Restraints 2103.3.7.8 Market and Technology Trends 2103.3.7.8.1 Market Trends 2103.3.7.8.2 Technology Trends 2113.3.7.9 Strategic Recommendations 2113.3.8 Vancomycin-resistant Enterococci 2123.3.8.1 Disease Background and Description 2123.3.8.2 Product Analysis: Instruments and Reagents 2153.3.8.3 Method Comparison 2153.3.8.4 Competitive Structure and Market Share Analysis 2173.3.8.5 Market Forecasts 2183.3.8.5.1 Revenue Forecasts 2183.3.8.6 Market Challenges 2193.3.8.6.1 Market Drivers 2193.3.8.6.2 Market Restraints 2193.3.8.7 Market and Technology Trends 2193.3.8.7.1 Market Trends 2193.3.8.7.2 Technology Trends 2203.3.8.8 Strategic Recommendations 2203.3.9 Herpes Simplex Virus 2213.3.10 C. difficile 2213.3.11 Cytomegalovirus 2223.4 Blood Screening 2223.4.1 Product Analysis: Instruments and Reagents 2243.4.2 Method Comparison 2263.4.3 Blood Screening Market Size 2273.4.4 Competitive Positions 2283.4.5 Market Challenges and Strategic Recommendations 2333.4.5.1 Market Drivers and Restraints 2333.4.5.1.1 Market Drivers 2333.4.5.1.2 Market Restraints 2333.4.5.2 Market and Technology Trends 2343.4.5.2.1 Market Trends 2343.4.5.2.2 Technology Trends 2353.4.5.3 Strategic Recommendations 2354. Molecular Diagnostic Testing Technology for Infectious Disease Testing 2364.1 Infectious Disease Diagnostic Tests 2364.1.1 Molecular Diagnostic Tools Solutions 2384.1.2 Technology of Gene Expression Analysis 2384.1.2.1 Amplification and Detection of RNA 2384.1.2.2 Analysis of Multiple Genes 2394.1.2.3 Advanced Information Technology 2404.2 Use of Molecular Tests in Infectious Disease 2404.2.1 Molecular Screening 2404.2.2 Early Detection 2414.2.3 Detection of Specific Resistance Genes and Viral Loading Tests 2414.2.4 Pharmacogenomics and Personalized Medicine in MD Infectious Disease Testing 2414.2.5 Molecular Strain Typing 2434.3 Cost of Molecular Diagnostic Testing 2454.4 Use of Multiplex PCR Tests 2454.4.1 Advantages of Multiplex PCR 2454.4.2 Applications of Multiplex PCR 2464.5 Next-Generation Sequencing 2474.6 Patient Flow Software 2494.7 Digital PCR 2494.8 LAMP 2494.9 Ion Proton System for Gene Sequencing 2505. Business 2525.1 Technology and Market Trends 2525.1.1 Technology Trends 2525.2 M&A Activity 2555.3 Partnerships 2585.4 Competitive Analysis 2615.4.1 Primary Competitors 2615.4.2 Industry Challenges and Strategic Recommendations 2625.4.3 Commercialization of Molecular Diagnostic Products 2635.5 Intellectual Property Rights 2635.5.1 New Patents 2655.5.2 Current Patent Disputes 2655.6 Opportunities and Strategic Recommendations 2665.6.1 The Key Technical Opportunities with Significant Market Appeal in the Molecular Diagnostic Space in the Next Five Years 2665.6.2 Developments for Molecular Diagnostic Instrumentation Products 2665.6.3 Market Penetration Strategies for Infectious Disease Testing 2675.7 Business Models and Requirements for a Successful Molecular Diagnostics Infectious Disease Products Industry 2675.7.1 Scope of This Section 2675.7.2 The Success Achieved by the Molecular Diagnostics Infectious Disease Products 2675.7.3 Business Models in Molecular Diagnostics Infectious Disease Products 2685.7.4 SWOT Comparison of Business Models for MD Infectious Disease Diagnostic Testing 2695.7.5 Commercial Manufacturing of Molecular Diagnostics Infectious Disease Products: Requirements 2825.7.5.1 Elements of Commercial Manufacturing 2825.7.5.1.1 Regulatory Requirements 2825.7.5.1.2 Manufacturing Process Scale 2825.7.5.1.3 In-House Manufacturing 2835.7.5.2 Contract Manufacturing: Commercial and Academic 2835.7.6 Sales and Marketing Strategies for Infectious Disease Tests 2845.8 Companion Diagnostics Development in Partnership with a Pharmaceutical Company 2885.8.1 Description of Business Model 2885.8.2 Anti-Infective Pharmaceutical Market 2926. Reimbursement and Billing Landscape for Molecular Diagnostics Testing for Infectious Disease 2996.1 Overview 2996.1.1 Gap Filling 3006.2 Trends in Reimbursement Practice 3006.2.1 Medicare Reimbursement Threats 3026.2.2 Analysis of ROI for Molecular Diagnostic Tests for Infectious Disease Using Current Medicare Reimbursement Rules 3056.3 Trends in Patient Care and Reimbursement 3056.4 Revenue Threats 3076.4.1 Medicare Payment Exceptions 3086.4.2 Three Areas for Denial of Claims 3086.5 Billing Rules 3096.5.1 Medicare Billing Procedures 3096.5.2 Medicare CPT Coding Rules for MD Infectious Disease Testing 3106.5.3 Infectious Disease Billing Strategies 3117. Regulatory Requirements 3137.1 U.S. Food and Drug Administration 3137.2 CLIA Regulations 3137.3 Clinical Laboratory Improvement Act 3157.4 State Licensing for Service Laboratories 3167.5 IVDMIAs 3167.6 FDA Draft Guidance on In Vitro Companion Diagnostic Devices 3177.7 510(k) Clearance 3177.8 Pre-Market Approval (PMA) 3187.8.1 Pre-Market Approval Application 3197.9 Analyte Specific Reagents (ASRs) 3197.9.1 Laboratory Developed Tests (LDT) 3207.10 What Regulatory Guidance is Needed for Companion Biomarkers? 3217.11 U.S. Patent and Trademark Office (USPTO) 3237.12 IRB Approval in Clinical Trials 3237.13 CE Marking and the European In Vitro Diagnostic Device Directive 3237.14 De Novo Classification 3237.15 Research Use Only Reagents 3247.16 FDA Recommendations on Methicillin-Resistant Staphylococcus aureus and Staphylococcus aureus Testing 3248. Business Decisions using Molecular Diagnostic Tests in Infectious Disease Testing 3288.1 What are Key Opportunities in Infectious Disease Testing Development and Commercialization? 3288.3 How do Business Strategies, Such as Those Relating to Acquisition, Drive MD Strategies? 3298.4 How Might Novel Infectious Disease MD Test Development Lead to Acquisition Strategies and Their Implications for Deal Making? 3298.5 How can Molecular Diagnostic Tests Increase Value in an Associated Drug Marketing Plan? 3308.6 Which Types of Infectious Disease MD Testing Should be Developed by Diagnostic Companies at Various Stages in the Development Pipeline? 3308.7 How can Regulatory Oversight Drive Approval and Adoption of New Technologies? 3318.8 What are the Noteworthy Deals? 3318.9 Who are the Acquirers? 3328.10 Who are the Target Companies? 3328.11 How will Platform Technology Companies Enter the Space? 3328.12 Will Pharma Integrate with Diagnostics? 3348.13 How do Platform Technology Companies Position Themselves for Diagnostics Development? 3348.14 Evaluate How Partnering and M&As will Alter the Competitive Landscape 3358.15 Predict How FDA Regulations will Impact New Diagnostic Tests 3358.16 How can Big Pharma and Diagnostic Companies Co-Develop Biomarkers in a Model for Regulatory Acceptance? 3368.17 How to Maximize Business Development Through Biomarker Strategies? 3368.18 What is the Best Type of Business Model for Developing Genetic Biomarkers for Infectious Disease? 3378.19 How Best have Genetic Biomarkers Provided the Most Benefit in Infectious Disease Testing? 3378.20 What are the Most Innovative Methods in Development of Molecular Diagnostic Biomarkers? 3378.21 What are the Best Values for Genetic Biomarkers in Drug Development and in Diagnostics? 338FDA Clears Gen-Probe's PANTHERAE System for use with APTIMA Combo 2AE Assay in May 2012 3389. Economics of Anti-Microbial Drug Resistance: The Persistent Need for Antibacterials 3419.1 Resistance and Antibiotic Usage 3459.2 Infection Control Programs 34710. Company Profiles 34810.1 Abbott Laboratories 34810.2 AdvanDx 35110.3 Arcxis Biotechnologies 35210.4 Atlas 35210.5 AutoGenomics, Inc. 35310.6 Becton, Dickinson and Company 35410.7 bioMErieux 35610.8 Biocartis 35610.9 bioTheranostics 35710.10 Cepheid 35810.11 EraGen Biosciences 35910.12 GenMark Diagnostics, Inc. 36010.13 Genomix Biotech 36010.14 Hologic Gen-Probe 36110.15 Genomica S.A.U. 36610.16 Great Basin Corporation 36710.17 Illumina, Inc. 36710.18 Innogenetics NV 36810.19 Life Technologies 37010.20 Mobidiag 37210.21 Myconostica 37210.22 Myriad Genetics, Inc. 37210.23 Nanosphere 37410.24 NorDiag ASA (The DiaSorin Group) 37610.25 Qiagen NV 37610.26 Roche Ltd. 37910.27 Seegene 38010.28 SIRS-Lab 38110.29 TrimGen 38110.30 TrovaGene 38110.31 Veredus Laboratories 38110.32 Veridex 382Appendix 1: Draft Guidance for Industry and Food and Drug Administration StaffoEstablishing the Performance Characteristics of Nucleic Acid-based In Vitro Diagnostic Devices for the Detection and Differentiation of Methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus (SA) 383Appendix 2: Molecular Diagnostic Instruments with Combined Functions - Draft Guidance for Industry and Food and Drug Administration Staff 406Appendix 3: Applications for Molecular Testing 411INDEX OF FIGURESFigure 2.1: Relationship of DNA Testing to Key Areas of Clinical Diagnosis 29Figure 2.2: Finding Genes with Microassays 30Figure 2.3: The Use of Microassays for Studying Gene Expression 31Figure 2.4: Overall Structure of Nucleic Acid Testing Market 42Figure 3.1: Global Market fo新蒲崗迷你倉 Molecular Diagnostics, 2002-2017 50Figure 3.2: Global Market for Molecular Diagnostics Testing, 2012 53Figure 3.3: Share of Molecular Diagnostics Testing by Testing Type, 2012 54Figure 3.4: Key Players Market Share in Global Molecular Diagnostics Testing Markets, 2012 55Figure 3.5: Global Market for Infectious Disease Treatments, 2008-2014 56Figure 3.6: Global Revenue for Molecular Diagnostics Testing for Infectious Disease, 2009-2018 57Figure 3.7: U.S. Market Revenue for Molecular Diagnostics Testing for Infectious Disease, 2009-2018 58Figure 3.8: Infectious Disease Testing Revenue Market Share of Total U.S. MD Market, 2012 and 2018 59Figure 3.9: European Market Revenue for Molecular Diagnostics Testing for Infectious Disease, 2009-2018 60Figure 3.10: Japanese Market Revenue for Molecular Diagnostics Testing for Infectious Disease, 2009-2018 61Figure 3.11: Rest of World (ROW) Market Revenue for Molecular Diagnostics Testing for Infectious Disease, 2009-2018 61Figure 3.12: Infectious Disease Testing Revenue Market Share by Region, 2012 and 2018 62Figure 3.13: Total Global Infectious Disease Molecular Diagnostics Markets, 2012 63Figure 3.14: Total U.S. Infectious Disease Molecular Diagnostics Markets, 2012 63Figure 3.15: Total Global Infectious Disease Molecular Diagnostics Markets, 2018 65Figure 3.16: Total U.S. Infectious Disease Molecular Diagnostics Markets, 2018 65Figure 3.17: Global Trend of HIV Infection, 1991-2011 69Figure 3.18: Number of People Living with HIV, Newly Infected with HIV and Number of AIDS Deaths in the World, 1990-2011 70Figure 3.19: Worldwide Rate of New HIV Cases, 1990-2011 71Figure 3.20: Percentage of Adult Population in African Countries with HIV, 2010 72Figure 3.21: Global View of HIV Infection, 2009 74Figure 3.22: Ethnic Distribution of AIDS Patients in the U.S., 2011 74Figure 3.23: Ten Best Selling AIDS Drugs in the U.S., 2011 75Figure 3.24: U.S. Rates for New HIV Cases, 2011 75Figure 3.25: U.S. Rates for New HIV Cases in Men, 2010 76Figure 3.26: U.S. Rates for New HIV Cases in Women, 2010 76Figure 3.27: Proposed HIV Testing Algorithm 84Figure 3.28: Distribution of HIV Molecular Diagnostic Testing by Purpose 86Figure 3.29: Estimated Market for Global HIV Molecular Diagnostic Testing, 2011-2016 87Figure 3.30: Estimated Market for U.S. HIV Molecular Diagnostic Testing, 2011-2018 88Figure 3.31: Market Share Viral Load HIV MD Diagnostic Testing 89Figure 3.32: Geographic Distribution of Chronic HBV Infection 96Figure 3.33: Reported Cases of Acute Hepatitis A, B and C Infections in the U.S., 2005-2010 97Figure 3.34: Global Prevalence of Hepatitis C 107Figure 3.35: Primary Causes of Chronic Liver Disease 109Figure 3.36: Incidence of Acute Hepatitis C by Age Group o United States, 1992n2009 110Figure 3.37: Hepatitis C Infection by Source 110Figure 3.38: Growth and Projections of HCV Therapies by Drug Class, 2008 and 2013 111Figure 3.39: U.S. Market Share of HCV Molecular Diagnostic Market, 2012 122Figure 3.40: Global Market Share (Excluding U.S.) of HCV Molecular Diagnostic Market, 2012 122Figure 3.41: Rate of New Cases and Deaths of Cervical Cancer by Age Group Worldwide, 1980-2010 130Figure 3.42: Hybrid Capture 2 (HC2) versus PCR - Analytical Sensitivity and Clinical Sensitivity 134Figure 3.43: Basic Steps in Hybrid Capture 2 Technology 135Figure 3.44: U.S. Market Share of HPV Molecular Diagnostic Market, 2012 140Figure 3.45: Global Market Share (Excluding U.S.) of HPV Molecular Diagnostic Market, 2012 140Figure 3.46: Market Share Estimates for Molecular Diagnostic HPV Testing, 2012 141Figure 3.47: Number of Reported and Confirmed Cases of Influenza by Virus Sub-Type Worldwide, 2013 153Figure 3.48: Distribution of H1N1 Flu in the U.S., 2013 154Figure 3.49: H1N1 Confirmed and Probable Case Rate in the U.S., By Age Group 155Figure 3.50: U.S. Rates of Sexually-transmitted Diseases, 1940-2010 162Figure 3.51: U.S. Market Share of Chlamydia/Gonorrhea Molecular Diagnostic Market, 2012 164Figure 3.52: Global Market Share (Excluding U.S.) of Chlamydia/Gonorrhea Molecular Diagnostic Market, 2012 164Figure 3.53: Chlamydia Infection Rates: Total and by Gender: U.S., 1989-2010 168Figure 3.54: Chlamydia U.S. Prevalence by Age Group and Race/Ethnicity 169Figure 3.55: U.S. and Outlying Areas Gonorrhea Infection Rates, 1941-2011 176Figure 3.56: U.S. Gonorrhea Infection Rates by Race/Ethnicity, 1999-2011 177Figure 3.57: Pipeline for TB Diagnostics, 2005-2015 186Figure 3.58: The Development Pipeline for New TB Drugs, July 2012 186Figure 3.59: Number of Tuberculosis Cases Among U.S.- and Foreign-Born Persons in the U.S., 1993-2011 187Figure 3.60: Rate of Tuberculosis Cases Among U.S.- and Foreign-Born Persons in the U.S., 1993-2011 187Figure 3.61: Rate of Tuberculosis Cases by State/Area in the U.S., 2011 189Figure 3.62: U.S.-Born Tuberculosis Cases by Ethnicity, 2011 190Figure 3.63: Reported Tuberculosis Cases in the U.S., 1983-2011 194Figure 3.64: Global Market Share of MD TB Testing 195Figure 3.65: Global Market Share of MD TB Testing by Region, 2012 196Figure 3.66: Incidence Rates of Invasive MRSA Infections by Age 203Figure 3.67: MRSA Trends According to Patient Location, 1998-2005 203Figure 3.68: Incidence of Healthcare-Associated MRSA Infections, 2005-2008 204Figure 3.69: U.S. Market Share of MRSA Molecular Diagnostic Market, 2012 208Figure 3.70: Global Market Share (Excluding U.S.) of MRSA Molecular Diagnostic Market, 2012 208Figure 3.71: Global Frequency of Vancomycin-Resistant Enterococci, 2006 214Figure 3.72: U.S. Market Share of VRE Molecular Diagnostic Market, 2012 218Figure 3.73: Estimated Market for Global Blood Screening Product Sales, 2007-2019 228Figure 3.74: Hologic Gen-Probe Blood Screening Product Net Sales, 2005-2009 229Figure 3.75: Blood Screening Product Market Share by Company, 2012 231Figure 4.1: Using DNA Microassays to Measure Gene Expression 236Figure 4.2: Schematic of Molecular Diagnostics for Studying Gene Expression in Patients 237Figure 4.2: Schematic of Molecular Diagnostics for Studying Gene Expression in Patients 242Figure 5.1: FDA Co-developed Products as a Model for Collaboration 259Figure 5.2: Market Growth of MD Infectious Disease Tests 285Figure 5.3: Segmentation of the Biomarker Development Market 289Figure 5.4: Global Distribution of Anti-infective Agent Sales by Geography 292Figure 5.5: Leading Companies in Anti-infectives Market Share, 2011 294Figure 6.1: Reimbursement for Diagnostics in Healthcare Decision Making 302Figure 9.1: Global Multidrug Susceptibility in Pseudomonas aeruginosa 343Figure 9.2: Global Frequency of Vancomycin-Resistant Enterococci, 2006 344INDEX OF TABLESTable 1.1: Market Trends in Infectious Disease DNA Testing 22Table 1.2: Molecular Diagnostics Infectious Disease Market: Market Drivers Ranked in Order of Impact 23Table 1.3: Molecular Diagnostics Infectious Disease Market: Market Restraints Ranked in Order of Impact 23Table 1.4: Strategic Recommendations on Molecular Diagnostic Sector Business Functions 23Table 2.1: Top Ten Causes of Death Worldwide 33Table 2.2: The Most Prevalent Infectious Diseases Worldwide 34Table 2.3: Annual Rates of Global Infectious Diseases 37Table 2.4: Emerging Molecular Diagnostic Technologies 40Table 2.5: Automated Molecular Diagnostics Platforms for Infectious Disease Testing 43Table 2.6: Companies Marketing Multiple Products in Molecular Diagnostics Infectious Disease Sector 43Table 2.7: FDA-Approved Molecular Diagnostic Commercial Kits for the Detection of Infectious Agents 45Table 2.8: Global and U.S. Major Infectious Disease Market Size (Estimated Infected Persons) 45Table 2.9: Molecular Diagnostics Market: Market Drivers Ranked in Order of Impact 46Table 2.10: Molecular Diagnostics Market: Market Restraints Ranked in Order of Impact 46Table 2.11: Attractive Growth Areas for Molecular Diagnostic Testing 48Table 2.12: NAT Labs in U.S. and Five European Markets 48Table 3.1: Global Market for Molecular Diagnostics Testing, 2000-2017 51Table 3.2: U.S. Market for Molecular Diagnostics Testing, 2004-2018 51Table 3.3: European Market for Molecular Diagnostics Testing, 2005-2018 52Table 3.4: Japanese Market for Molecular Diagnostics Testing, 2009-2018 52Table 3.5: Summary of Molecular Diagnostics Testing Sectors 53Table 3.6: Share of Molecular Diagnostics Testing by Testing Type, 2012 54Table 3.7: Key Players and Market Share in Global Molecular Diagnostics Testing Market 2012 54Table 3.8: Revenue Model for Molecular Diagnostics Testing 55Table 3.9: Molecular Infectious Disease Diagnostics Market: Market Drivers Ranked in Order of Impact 56Table 3.10: Molecular Infectious Disease Diagnostics Market: Market Restraints Ranked in Order of Impact 56Table 3.11: Global Revenue for Molecular Diagnostics Testing for Infectious Disease, 2009-2018 57Table 3.12: U.S. Market Revenue for Molecular Diagnostics Testing for Infectious Disease, 2009-2018 58Table 3.13: European Market Revenue for Molecular Diagnostics Testing for Infectious Disease, 2009-2018 59Table 3.14: Japanese Market Revenue for Molecular Diagnostics Testing for Infectious Disease, 2009-2018 60Table 3.15: Rest of World (ROW) Market Revenue for Molecular Diagnostics Testing for Infectious Disease, 2009-2018 60Table 3.16: Molecular Diagnostic Markets for Infectious Disease Testing, 2012 63Table 3.17: Molecular Diagnostic Markets for Infectious Disease Testing, 2018 64Table 3.18: Business Factors Influencing Advanced Infectious Disease MD Testing Services 66Table 3.19: Global Summary of the HIV/AIDS Epidemic, 2011 70Table 3.20: Global HIV Statistics, 2011 73Table 3.21: HIV Resistance Testing Recommendations 77Table 3.22: Summary of Assays for HIV Viral Load Testing 77Table 3.23: Commercially Available Molecular Diagnostic Products for HIV Assay 83Table 3.24: Global Market for Molecular Diagnostic HIV Testing, 2007-2012 86Table 3.25: U.S. Market for HIV Molecular Diagnostic Testing, 2007-2012 87Table 3.26: Global Market for Molecular Diagnostic HIV Diagnostic Testing, 2013-2018 88Table 3.27: U.S. Market for Molecular Diagnostic HIV Diagnostic Testing, 2013-2018 88Table 3.28: Global Market for HIV Viral Load Diagnostic Testing, 2007-2012 89Table 3.29: U.S. Market for HIV Viral Load Diagnostic Testing, 2007-2012 89Table 3.30: Global Market for HIV Viral Load Diagnostic Testing, 2013-2018 90Table 3.31: U.S. Market for HIV Viral Load Diagnostic Testing, 2013-2018 90Table 3.32: HIV Molecular Diagnostics Market: Market Drivers Ranked in Order of Impact 91Table 3.33: HIV Molecular Diagnostics Market: Market Restraints Ranked in Order of Impact 92Table 3.34: Clinical Application of Quantitative HBV DNA Testing 97Table 3.35: Lower Detection Limits of HBV DNA Assays 99Table 3.36: Summary of Molecular Diagnostic Assays for Testing HBV 101Table 3.37: Global Market for HBV Diagnostic Testing, 2000-2012 101Table 3.38: U.S. Market for HBV Diagnostic Testing, 2000-2012 102Table 3.39: Global Market for HBV Diagnostic Testing, 2013-2018 102Table 3.40: U.S. Market for HBV Diagnostic Testing, 2013-2018 102Table 3.41: HBV Molecular Diagnostics Market: Market Drivers Ranked in Order of Impact 103Table 3.42: HBV Molecular Diagnostics Market: Market Restraints Ranked in Order of Impact 103Table 3.43: Hepatitis B Facts 106Table 3.44: U.S. HCV Statistics 111Table 3.45: Worldwide Rate of HCV Cases 112Table 3.46: Efficiency of Available HCV Screening Tests 113Table 3.47: Commercially Available Molecular Diagnostic Products for HCV Assay 120Table 3.48: Global Market for DNA HCV Diagnostic Testing, 2005-2012 121Table 3.49: U.S. Market for DNA HCV Diagnostic Testing, 2005-2012 121Table 3.50: Global Market for NAT HCV Diagnostic Testing, 2013-2018 121Table 3.51: U.S. Market for NAT HCV Diagnostic Testing, 2013-2018 121Table 3.52: Major Companies Marketing HCV Molecular Diagnostic Tests: Market Size and Share, 2012 122Table 3.53: HCV Molecular Diagnostics Market: Market Drivers Ranked in Order of Impact 123Table 3.54: HCV Molecular Diagnostics Market: Market Restraints Ranked in Order of Impact 124Table 3.55: Recommendations for HCV Diagnostic Testing 126Table 3.56: Number of Pap Smears Performed by Country, 2009 128Table 3.57: Deaths in Thousands from Cervical Cancer by Region and by Age Group in 2011 130Table 3.58: Qiagenis Digene HC2 High-risk HPV DNA Test 133Table 3.59: Commercially Available Molecular Diagnostic Products for HPV Assay 138Table 3.60: Major Companies Marketing HPV Molecular Diagnostic Tests: Market Size and Share, 2012 140Table 3.61: Global Market for HPV Molecular Diagnostic Testing, 2007-2012 144Table 3.62: U.S. Market for HPV Molecular Diagnostic Testing, 2007-2012 144Table 3.63: Global Market for HPV Molecular Diagnostic Testing, 2013-2018 144Table 3.64: U.S. Market for HPV Molecular Diagnostic Testing, 2013-2018 144Table 3.65: HPV Molecular Diagnostics Market: Market Drivers Ranked in Order of Impact 145Table 3.66: HPV Molecular Diagnostics Market: Market Restraints Ranked in Order of Impact 145Table 3.67: Commercially Available Molecular Diagnostic Products for Influenza Assay 157Table 3.68: Global Market for Molecular Influenza Diagnostic Testing, 2007-2012 158Table 3.69: U.S. Market for DNA Influenza Diagnostic Testing, 2007-2012 158Table 3.70 Global Market for Influenza Molecular Diagnostic Testing, 2013-2018 158Table 3.71: U.S. Market for Influenza Molecular Diagnostic Testing, 2013-2018 159Table 3.72: Influenza Molecular Diagnostics Market: Market Drivers Ranked in Order of Impact 159Table 3.73: Influenza Molecular Diagnostics Market: Market Restraints Ranked in Order of Impact 159Table 3.74: Global Market for Molecular Diagnostic Chlamydia/Gonorrhea Diagnostic Testing, 2000-2012 163Table 3.75: U.S. Market for Molecular Diagnostic Chlamydia/Gonorrhea Diagnostic Testing, 2000-2012 163Table 3.76: Major Companies Marketing Chlamydia/Gonorrhea Molecular Diagnostic Tests: Market Size and Share, 2012 164Table 3.77: Global Market for Chlamydia/Gonorrhea Diagnostic Testing, 2013-2018 165Table 3.78: U.S. Market for Chlamydia/Gonorrhea a Diagnostic Testing, 2013-2018 165Table 3.79: U.S. Chlamydia Infection Rates, 1985-2011 167Table 3.80: U.S. Chlamydia Statistics 168Table 3.81: Commercially Available Molecular Diagnostic Products for Chlamydia Assay 171Table 3.82: Global Market for Chlamydia Molecular Diagnostic Testing, 2012-2018 172Table 3.83: U.S. Market for Chlamydia Molecular Diagnostic Testing, 2012-2018 172Table 3.84: Chlamydia Molecular Diagnostics Market: Market Drivers Ranked in Order of Impact 173Table 3.85: Chlamydia Molecular Diagnostics Market: Market Restraints Ranked in Order of Impact 173Table 3.86: U.S. Gonorrhea Statistics 178Table 3.87: Commercially Available Molecular Diagnostic Products for Gonorrhea Assay 181Table 3.88: Major Companies Marketing /Gonorrhea Molecular Diagnostic Tests: Market Size and Share, 2012 181Table 3.89: Gonorrhea Molecular Diagnostics Market: Market Drivers Ranked in Order of Impact 182Table 3.90: Gonorrhea Molecular Diagnostics Market: Market Restraints Ranked in Order of Impact 182Table 3.91: Commercially Available Molecular Diagnostic Assays for Testing TB 193Table 3.92: Global Market for MD TB Diagnostic Testing, 2005-2012 194Table 3.93: U.S. Market for MD TB Diagnostic Testing, 2005-2012 195Table 3.94: Global Market Share of MD TB Testing by Region, 2012 195Table 3.95: Global Unit Sales of MD TB Testing by Region, 2012 196Table 3.96: Comparative U.S. Claim Charges for TB Testing by Type, 2012 197Table 3.97: Global Testing for TB by Testing Type, 2012 197Table 3.98: Global Testing for TB by Testing Reason, 2012 197Table 3.99: Global Market for MD TB Diagnostic Testing, 2013-2018 197Table 3.100: U.S. Market for MD TB Diagnostic Testing, 2013-2018 198Table 3.101: Tuberculosis Molecular Diagnostics Market: Market Drivers Ranked in Order of Impact 198Table 3.102: Tuberculosis Molecular Diagnostics Market: Market Restraints Ranked in Order of Impact 198Table 3.103: Leading Tuberculosis Therapeutic R&D Candidates 201Table 3.104: Commercially Available Molecular Diagnostic Products for MRSA Assay 206Table 3.105: Global Market for MRSA Diagnostic Testing, 2005-2012 206Table 3.106: U.S. Market for MRSA Diagnostic Testing, 2005-2012 207Table 3.107: Major Companies Marketing MRSA Molecular Diagnostic Tests: Market Size and Share, 2012 207Table 3.108: Global Market for MD MRSA Diagnostic Testing, 2013-2018 209Table 3.109: U.S. Market for MD MRSA Diagnostic Testing, 2013-2018 209Table 3.110: MRSA Molecular Diagnostics Market: Market Drivers Ranked in Order of Impact 210Table 3.111: MRSA Molecular Diagnostics Market: Market Restraints Ranked in Order of Impact 210Table 3.112: In Vitro Susceptibility of Staphylococci to New Agents in Development 212Table 3.113: Commercially Available Molecular Diagnostic Products for VRE Assay 216Table 3.114: Global Market for VRE Diagnostic Testing, 2005-2To order this report:In_Vitro_Diagnostic Industry: Molecular Diagnostics in Infectious Disease TestingContact Clare: clare@reportlinker.comUS:(339) 368 6001Intl:+1 339 368 6001ReportlinkerWeb site: .reportlinker.com/mini storage

Source: Bangkok Post, ThailandAug.自存倉 20--The digital TV auction will be delayed to December or January to ensure the process runs smoothly, says the head of the broadcasting regulator.Col Natee Sukonrat, chairman of the National Broadcasting and Telecommunications Commission's broadcasting committee, said the information of memorandum (IM) for the auction will be announced on Aug 27 and the regulator will clarify some doubtful IM details to potential bidders on Sept 3.The auction document costing 1 million baht will be sold from Sept 10-12 and the NBTC will explain details about it on Oct 15.The NBTC will open applications from Oct 28-29 and will announce qualified applicants within 45 days.The auction will be held within 30 days (in December or January). The regulator will announce the certification of the auction within 15 days.Col Natee expects digital TV will start broadcasting around February or March next year, later than the previous expected date of Dec 5.The regulation on the digital TV auction method means licensed broadcasters must air their channels digitally within 45 days of the regulator certifying them."The three-month digital TV auction time frame aims to ensure a smooth process and provide opportunities to迷你倉新蒲崗a wide range of participants," Col Natee said.A source from one licensed network operator said the issue of network rental cost is still unclear due to a licence-issuing delay to facility providers.This means that four network providers _ Thai PBS, the Royal Thai Army, MCOT Plc and the Public Relations Department _ are finding it difficult to calculate the network rental cost.The NBTC has issued only one facility provider licence to Thai PBS, which has 18 main broadcast towers.According to the NBTC, there will be 39 main stations and 114 substations."Facilities are a key factor to calculate the network rental cost. Although we [Thai PBS, MCOT, the Royal Thai Army, Public Relations Department, TOT and CAT Telecom] have agreed to share our infrastructure, it's not easy to implement and clinch an official commercial agreement," a source said.Moreover, the unclear must-carry rule means channel operators must estimate the satellite-carrying cost.Col Natee said digital TV bidders will know network rental costs at least 30 days before the auction takes place.Copyright: ___ (c)2013 the Bangkok Post (Bangkok, Thailand) Visit the Bangkok Post (Bangkok, Thailand) at .bangkokpost.com Distributed by MCT Information Services迷你倉出租

未能提供文字內容。.迷你倉出租scmp.com/news/world/article/1297622/us-targets-lie-detector-coaches-following-edward-snowden-affair

王陽發　報道ongyh@sph.com.sg反映藍籌股走勢的海峽時報指數上周受到美國市場猛跌的衝擊，self storage支撐了24個交易日的3200點防線在上周五宣告失守，最後報3197.53點，全周下跌32.38點或1％。上周五美國隔夜市場持穩，但華爾街的道瓊斯指數已創下一年來最大單周跌幅——跌2.23％。市場人士預測海峽指數本周料嘗試重回3200點水平以上，但本周較遲時將出爐的多個海外經濟消息，包括中美經濟數據和美國聯邦儲備局方面的消息，最終將左右本周市場方向。鑫道投資分析公司（Voyage Research）研究部副主管黃建�表示：“本地市場一直是以美國政府公債收益率的走向馬首是瞻，本周料也將繼續如此。匯豐控股發佈的中國製造業採購經理指數預覽數據以及來自歐洲方面關於製造業採購經理指數的表現，也可能影響市場方向。由於美國聯邦儲備局本周可能調整其貨幣政策，本地股市交投可能繼續謹慎。海峽時報指數可能嘗試回到3200點水平。”市場不只預測美國將在9月開始削減量化寬鬆力度，還擔心時間會提前。因為這個削減量化寬鬆力度的可能，美國政府公債的收益率已大幅上漲，十年期美國公債收益率如今達到了2011年7月以來的最高。已有分析師說，美國股市在本月已見頂回跌，但市場看法不一。道瓊斯指數兩周來確實已從高峰下跌逾576點，上周五閉市僅稍在1萬5000點以上，是過去30個交易日以來最接近這個水平的一次。輝立期貨（Phillip Futures）分析師沈漢強指出，因美國可能在9月削減量化寬鬆力度，本地股市上周受投資者離開市場的影響而下跌。本周市迷你倉將關注的事項，美國方面有當地周三發佈的美國現有住宅的銷售數據、周四出爐的聯儲局公開市場委員會會議記錄，以及美國新宅銷售數據。匯豐控股本周四將發佈中國製造業採購經理指數預覽數據。在歐洲周四，法國和德國的製造業採購經理指數也將出爐。沈漢強預料海峽指數本周將繼續下跌，主要有以下幾個原因：首先，市場預期美國現有住宅的銷售和新宅的銷售，全都將取得改善。正面的數據將加強美國經濟複蘇的看法。這也將使美國聯儲局更有理由削減其每月850億美元的債券購買計劃（意即削減量化寬鬆力度）；第二，聯儲局公開市場委員會7月份的會議記錄，將為市場提供進一步的線索，以推測該局何時將減少量化寬鬆力度；第三，市場將繼續保持謹慎，直到該公開市場委員會在9月19日開會討論利率政策；他說，海指眼下的支持線和阻力線是3100點和3250點，下個支持線和阻力線是3050點和3300點。在美國方面，彭博社引述威爾斯資本管理公司（Wells Capital Management）首席投資策略師詹姆斯·保爾森（James Paulsen）指出：“市場需要消化三大事項。首先，它需要消化去年秋天至今這個很大的上漲走勢。我們還需要對利率的重大變化作出調整。我們將需要消化來自削減量化寬鬆力度的影響，而我相信聯儲局將在今年行動。”市場不只預測美國將在9月開始削減量化寬鬆力度，還擔心時間會提前。因為這個削減量化寬鬆力度的可能，美國政府公債的收益率已大幅上漲，十年期美國公債收益率如今達到了2011年7月以來的最高。已有分析師說，美國股市在本月已見頂回跌，但市場看法不一。文件倉